The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...
A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...
The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...
A Cochrane systematic review has found new moderate-quality evidence that tiotropium + long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS) combination therapy reduces hospital admission for ...
When added to ICS, tiotropium and LABAs perform similarly for asthma patients. What is the effect of ICS/LABA controller therapy on asthma in patients with persistent cold airway hyperresponsiveness, ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...
Please provide your email address to receive an email when new articles are posted on . Fluticasone-based inhaled corticosteroid treatment substantially changed airway microbiome diversity in patients ...
For patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment options include a long-acting beta-agonist (LABA) alone or a LABA combined with an inhaled corticosteroid ...
FDA approval - on ICS/LABA combinations in asthma | Regulatory NewsThe AUSTRI study is a global, multicentre, randomised stratified, double-blind, parallel-group active comparator, 26 week study in ...
At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an evening industry symposium. The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback